Blau Farmacêutica (BLAU3) Q3 2024 earnings summary

Executive summary

• Achieved record net revenue of BRL 474 million in 3Q24, up 31% year-over-year, driven by strong organic growth in the Hospital segment and successful new product launches.

• Gross margin rose to 39.5%, up 880bps year-over-year and 300bps sequentially, with improvement for the fourth consecutive quarter.

• Recurring EBITDA reached BRL 118 million, up 139% year-over-year, with margin at 24.9%.

• Recurring net income was BRL 69 million, 2.7x higher than 3Q23, with net margin at 14.6%.

• Cash conversion cycle improved to 218 days, a reduction of 54 days year-over-year, reflecting working capital optimization.

Financial highlights

• Net revenue for 9M24 was BRL 1,298 million, up 32% year-over-year.

• Gross profit for 3Q24 was BRL 187 million (+68% YoY), with gross margin at 39.5%.

• Recurring EBITDA margin reached 24.9% in 3Q24, up 1,130bps year-over-year.

• Net income for 9M24 was BRL 156.5 million, up 42% year-over-year.

• Operating cash flow in 9M24 was BRL 335 million, up 50% year-over-year.

Outlook and guidance

• Continued investment in R&D and production capacity, with four new production lines under construction and focus on monoclonal antibodies.

• Launch pipeline for 2024–2027 targets cumulative TAM of BRL 7.4 billion, with pipeline launches expected to reach BRL 714 million TAM in 2024.

• Management expects continued margin improvement as Bergamo integration advances, with full optimization targeted by end of 2025.

• Plans to maintain low leverage and prioritize cash generation amid high interest rates.

• Further expansion anticipated in Latin America and new productive lines targeted through 2027.